Analytical Data
-
Gene name
MBNL1
- Application
-
Alternative Names
Triplet-expansion RNA-binding protein
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NR56
-
Expression Region
1-382aa
-
Molecular Weight
53.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MBNL1 (Mbnl1, Muscleblind-like protein 1) is an RNA-binding protein that plays a crucial role in post-transcriptional regulation, particularly in muscle development and disease. Its significance is highlighted by its association with myotonic dystrophy type 1 (DM1), a genetic disorder caused by the expansion of CTG repeats in the DMPK gene, leading to MBNL1 sequestration and subsequent misregulation of numerous target mRNAs. Researchers have focused on the structural and functional characterization of MBNL1 to better understand its mechanisms and interactions in RNA binding. The recombinant expression of MBNL1 facilitates the study of its biochemical properties and interactions with RNA, providing insights into its role in alternative splicing and gene expression regulation. Moreover, understanding the reconstitution of MBNL1 can reveal the potential therapeutic targets for myotonic dystrophy and related disorders, making it a focal point in molecular biology and genetics research. Through structural biology approaches, including X-ray crystallography and NMR spectroscopy, the detailed understanding of its conformational dynamics and RNA recognition motifs has begun to emerge, opening avenues for developing strategies to counteract the pathological effects observed in RNA-mediated diseases.
